V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012548 | 160006034 | 1.8 | 103.7 | Disease modification (D) | 2016-05-31 | 2016-06-08 | DOXORUBICIN | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 101753237 |
| 160012549 | 160006035 | 1.85 | 65.9 | null | 2018-12-18 | 2019-01-10 | IMATINIB | 02 | null | TRIAL UNSPECIFIED | 100808736 |
| 160012550 | 160006036 | 1.61 | 118 | Palliative (P) | 2019-06-23 | 2019-06-23 | Cisplatin | 02 | N | LIPOSOMAL DOXORUBICIN | 100039296 |
| 160012552 | 160006037 | 1.79 | 70 | Neo-adjuvant (N) | 2016-12-11 | 2016-12-26 | Trial Unspecified | N | N | TRIAL UNSPECIFIED | 101442955 |
| 160012553 | 160006038 | 1.69 | 75.1 | Neo-adjuvant (N) | 2017-06-27 | 2017-07-04 | ETOP 13-18 BEAT-meso Trial | 02 | N | ENZALUTAMIDE | 100315448 |
| 160012554 | 160006039 | 1.72 | 64 | Adjuvant (A) | 2017-12-23 | 2017-12-30 | EW EuroEwing 2012 Arm B VDC | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100204942 |
| 160012557 | 160006040 | 1.82 | 95.6 | null | 2019-03-27 | 2019-04-13 | Doxorubicin + Olaratumab | N | N | NIVOLUMAB | 100793203 |
| 160012558 | 160006041 | 1.58 | 67.1 | Palliative (P) | 2017-12-16 | 2017-12-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100189513 |
| 160012559 | 160006042 | 1.76 | 70 | null | null | 2022-04-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100825657 |
| 160012560 | 160006043 | 1.69 | 82.5 | 03 | 2019-05-30 | 2019-05-31 | Bevacizumab+Carbo+Pacliaxel | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100138882 |
| 160012562 | 160006044 | 1.78 | 72.25 | Palliative (P) | 2019-04-18 | 2019-04-25 | ECF | N | N | TRIAL UNSPECIFIED | 100549914 |
| 160012564 | 160006045 | 1.8 | 79.3 | Palliative (P) | 2017-04-06 | 2017-04-14 | Trial Unspecified | 02 | null | TRIAL UNSPECIFIED | 101765665 |
| 160012567 | 160006046 | null | 81.5 | Curative (C) | 2015-09-29 | 2018-10-16 | Trial Unspecified | 02 | null | DOXORUBICIN + OLARATUMAB | 100892578 |
| 160012568 | 160006047 | 1.72 | 59.2 | Palliative (P) | 2017-03-26 | 2017-04-07 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101624041 |
| 160012573 | 160006048 | 1.69 | 63 | Palliative (P) | 2018-08-09 | 2018-08-09 | Bevacizumab+Carbo+Pacliaxel | N | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100549545 |
| 160012575 | 160006049 | 0 | 0 | Palliative (P) | 2019-01-26 | 2019-02-15 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101592647 |
| 160012577 | 160006050 | 1.65 | 52 | Palliative (P) | 2020-03-10 | 2020-03-24 | Doxorubicin + Ifosfamide | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101100314 |
| 160012579 | 160006051 | 1.68 | 88.3 | Neo-adjuvant (N) | 2017-05-19 | 2017-05-20 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 100588430 |
| 160012580 | 160006052 | 0 | 20 | Disease modification (D) | 2018-08-31 | 2018-09-13 | Trabectedin | 02 | N | LANREOTIDE | 100986676 |
| 160012583 | 160006053 | 1.75 | 94.4 | null | 2018-09-27 | 2018-09-27 | Trial Unspecified | 02 | null | TRIAL UNSPECIFIED | 100754920 |
| 160012584 | 160006054 | 1.66 | 86.1 | Curative (C) | 2017-05-20 | 2017-06-01 | Paclitaxel 7 day | 02 | N | IPILIMUMAB + NIVOLUMAB | 100139301 |
| 160012585 | 160006055 | 1.67 | 59.8 | Palliative (P) | 2017-12-08 | 2018-01-13 | Capecitabine | 02 | N | DOXORUBICIN + OLARATUMAB | 101674462 |
| 160012588 | 160006056 | 1.8 | 101.6 | Palliative (P) | 2018-03-24 | 2018-03-24 | VIDE | N | N | IFOSFAMIDE | 100279042 |
| 160012592 | 160006057 | 1.74 | 84 | Palliative (P) | 2017-10-27 | 2017-10-31 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 101835969 |
| 160012594 | 160006059 | 1.75 | 88 | Palliative (P) | 2018-08-17 | 2018-08-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100927274 |
| 160012595 | 160006060 | 1.71 | 73.1 | Neo-adjuvant (N) | 2020-02-15 | 2020-02-18 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100836346 |
| 160012596 | 160006061 | 1.74 | 59.9 | Palliative (P) | 2017-05-21 | 2017-05-21 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100134559 |
| 160012597 | 160006062 | 1.63 | 80.4 | Palliative (P) | 2019-07-09 | 2019-07-23 | Doxorubicin + Ifosfamide | 01 | N | CARBOPLATIN + VINORELBINE | 100879137 |
| 160012599 | 160006063 | 1.75 | 63.6 | Palliative (P) | 2016-07-03 | 2016-07-17 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101037498 |
| 160012603 | 160006064 | 1.76 | 96.7 | Neo-adjuvant (N) | 2019-05-09 | 2019-05-11 | Cisplatin + Pemetrexed | 2 | N | TRIAL UNSPECIFIED | 101055647 |
| 160012604 | 160006065 | 1.79 | 128 | Curative (C) | 2017-06-12 | 2017-06-13 | CVP R | 02 | N | GEMCARBO | 101665504 |
| 160012605 | 160006066 | 1.74 | 55 | Neo-adjuvant (N) | 2017-03-17 | 2017-03-17 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | CISPLATIN + DOXORUBICIN | 101614268 |
| 160012606 | 160006067 | 1.72 | 82.2 | Palliative (P) | null | 2018-04-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101664392 |
| 160012607 | 160006068 | 1.64 | 61 | Palliative (P) | 2016-08-29 | 2016-09-02 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 101343730 |
| 160012608 | 160006069 | 1.93 | 55 | Neo-adjuvant (N) | 2017-11-27 | 2017-12-25 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100830277 |
| 160012611 | 160006070 | 1.71 | 87.2 | Palliative (P) | null | 2017-11-03 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | DOXORUBICIN + OLARATUMAB | 101521195 |
| 160012616 | 160006071 | 1.75 | 89.2 | Curative (C) | 2016-10-11 | 2016-10-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100831944 |
| 160012617 | 160006072 | 1.7 | 69.5 | Palliative (P) | null | 2019-06-24 | EW EuroEwing 2012 Arm B VDC | 2 | null | EW EUROEWING 2012 ARM A VAI | 101375312 |
| 160012618 | 160006073 | 1.7 | 66.4 | Palliative (P) | 2016-07-18 | 2016-08-03 | Trial Unspecified | 02 | N | DOXORUBICIN | 101813083 |
| 160012621 | 160006074 | 1.57 | 88 | Palliative (P) | 2015-05-13 | 2015-06-24 | NB HRNBL-1 BUMEL MAT | N | N | CARBOPLATIN + PACLITAXEL | 100753275 |
| 160012622 | 160006075 | 0 | 58 | Palliative (P) | 2019-06-07 | 2019-06-07 | VIDE | 02 | N | TRIAL UNSPECIFIED | 101832210 |
| 160012623 | 160006076 | 1.85 | 50.8 | Neo-adjuvant (N) | 2016-05-25 | 2016-06-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101454197 |
| 160012624 | 160006077 | 1.76 | 71 | Palliative (P) | 2018-01-16 | 2018-01-31 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100321685 |
| 160012626 | 160006078 | 1.83 | 119 | Palliative (P) | 2018-08-12 | 2018-08-12 | Carboplatin + Etoposide iv&po | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101049683 |
| 160012627 | 160006079 | 1.71 | 47.6 | Curative (C) | 2019-07-07 | 2019-07-15 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100982489 |
| 160012628 | 160006080 | 1.76 | 90.8 | Palliative (P) | 2017-05-11 | 2017-05-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101710188 |
| 160012630 | 160006081 | 1.65 | 27.1 | Curative (C) | 2016-12-08 | 2016-12-26 | Doxorubicin + Olaratumab | 2 | N | VIDE | 100497117 |
| 160012631 | 160006082 | 1.66 | 72.2 | Palliative (P) | 2017-09-03 | 2017-09-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101212822 |
| 160012632 | 160006083 | 1.65 | 0 | null | 2019-02-23 | 2019-02-23 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100343837 |
| 160012633 | 160006084 | 1.79 | 47 | Adjuvant (A) | 2019-10-28 | 2019-10-29 | Trial Unspecified | N | N | TRIAL UNSPECIFIED | 100830771 |